Zoonotic Brazilian Vaccinia virus: From field to therapy

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 150-163

  Kroon, Erna Geessien ^a   Mota, Bruno Eduardo F ^a   Abrahão, Jônatas Santos ^a   Fonseca, Flávio Guimarães da ^a,b   Trindade, Giliane de Souza ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antiviral drugs; Bovine vaccinia (BV); Occupational disease; Orthopoxvirus; Vaccinia virus (VACV); Zoonosis

Indexed keywords

ARRABIDAEA SCEPTRUM EXTRACT; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; GEFITINIB; IMATINIB; IMIQUIMOD; NIGERICIN; PLANT EXTRACT; POLYGONUM SPECTABILE EXTRACT; RIBAVIRIN; SOLANUM PANICULATUM EXTRACT; TECOVIRIMAT; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; ZEYHERIA TUBERCULOSA EXTRACT;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARRABIDAEA SCEPTRUM; ATOMIC FORCE MICROSCOPY; BRAZIL; CONDYLOMA ACUMINATUM; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNOPHARMACOLOGY; GENE SEQUENCE; HUMAN; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; INFLAMMATION; MEDICINAL PLANT; MICROBIAL DIVERSITY; MOLECULAR BIOLOGY; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYGONUM SPECTABILE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SMALLPOX; SOLANUM PANICULATUM; VACCINIA VIRUS; VIRUS TRANSMISSION; ZEYHERIA TUBERCULOSA; ZOONOTIC BRAZILIAN VACCINIA VIRUS;

ANIMALS; BRAZIL; CATTLE; CATTLE DISEASES; HUMANS; MOLECULAR EPIDEMIOLOGY; OCCUPATIONAL DISEASES; PHYLOGENY; POLYMORPHISM, GENETIC; VACCINIA; VACCINIA VIRUS; ZOONOSES;

BOS; BOVINAE; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 80054862219     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.018     Document Type: Review

References (138)

1. Abrahão J.S., Guedes M.I., Trindade G.S., Fonseca F.G., Campos R.K., Mota B.F., Lobato Z.I., Silva-Fernandes A.T., Rodrigues G.O., Lima L.S., Ferreira P.C., Bonjardim C.A., Kroon E.G. One more piece in the VACV ecological puzzle: could peridomestic rodents be the link between wildlife and bovine vaccinia outbreaks in Brazil?. PLoS One 2009, 19:e7428.
2. Abrahão J.S., Trindade Gde S., Ferreira J.M., Campos R.K., Bonjardim C.A., Ferreira P.C., Kroon E.G. Long-lasting stability of Vaccinia virus strains in murine feces: implications for virus circulation and environmental maintenance. Arch. Virol. 2009, 154:1551-1553.
3. Abrahão J.S., Oliveira T.M., Campos R.K., Madureira M.C., Kroon E.G., Lobato Z.I. Bovine vaccinia outbreaks: detection and isolation of vaccinia virus in milk samples. Foodborne Pathog. Dis. 2009, 6:1141-1146.
4. Abrahão J.S., Lima L.S., Assis F.L., Alves P.A., Silva-Fernandes A.T., Cota M.M., Ferreira V.M., Campos R.K., Mazur C., Lobato Z.I., Trindade G.S., Kroon E.G. Nested-multiplex PCR detection of Orthopoxvirus and Parapoxvirus directly from exanthematic clinical samples. Virol. J. 2009, 6:140.
5. Abrahão J.S., Silva-Fernandes A.T., Lima L.S., Campos R.K., Guedes M.I., Cota M.M., Assis F.L., Borges I.A., Souza-Júnior M.F., Lobato Z.I., Bonjardim C.A., Ferreira P.C., Trindade G.S., Kroon E.G. Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg. Infect. Dis. 2010, 16:976-979.
6. Abrahão J.S., Silva-Fernandes A.T., Assis F.L., Guedes M.I., Drumond B.P., Leite J.A., Coelho L.F., Turrini F., Fonseca F.G., Lobato Z.I., Madureira M., Ferreira P.C., Bonjardim C.A., Trindade G.S., Kroon E.G. Human Vaccinia virus and Pseudocowpox virus co-infection: clinical description and phylogenetic characterization. J. Clin. Virol. 2010, 48:69-72.
7. Altmann S.E., Jones J.C., Schultz-Cherry S., Brandt C.R. Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide. Virology 2009, 388:248-259.
8. Andrade A.A., Silva P.N., Pereira A.C., De Sousa L.P., Ferreira P.C., Gazzinelli R.T., Kroon E.G., Ropert C., Bonjardim C.A. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem. J. 2004, 381:437-446.
9. Ara M., Zaballos P., Sanchez M., Querol I., Zubiri M.L., Simal E., Hörndler C. Giant and recurrent orf virus infection in a renal transplant recipient treated with imiquimod. J. Am. Acad. Dermatol. 2008, 58:S39-S40.
10. Arican O. Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children. Pediatr. Int. 2006, 48:403-405.
11. Batista V.H., Scremin J., Aguiar L.M., Schatzmayr H.G. Vulvar infection and possible human-to-human transmission of bovine poxvirus disease. Virus Rev. Res. 2009, 14:1-10.
12. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., Snyder J.T., Ahlers J.D., Franchini G., Moss B., Berzofsky J.A. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 2003, 100:9458-9463.
13. Berhanu A., King D.S., Mosier S., Jordan R., Jones K.F., Hruby D.E., Grosenbach D.W. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 2009, 53:4999-5009.
14. Berhanu A., King D.S., Mosier S., Jordan R., Jones K.F., Hruby D.E., Grosenbach D.W. Impact of ST-246(R) on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 2010, 29:289-303.
15. Bhanuprakash V., Venkatesan G., Balamurugan V., Hosamani M., Yogisharadhya R., Gandhale P., Reddy K.V., Damle A.S., Kher H.N., Chandel B.S., Chauhan H.C., Singh R.K. Zoonotic infections of buffalopox in India. Zoonoses Public Health 2010, 57:e149-e155.
16. Blasco R., Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37, 000-Dalton outer envelope protein. J. Virol. 1991, 65:5910-5920.
17. Brandao G.C., Kroon E.G., Duarte M.G., Braga F.C., Filho J.D., de Oliveira A.B. Antimicrobial, antiviral and cytotoxic activity of extracts and constituents from Polygonum spectabile Mart. Phytomedicine 2010, 17:926-929.
18. Brandao G.C., Kroon E.G., dos Santos J.R., Stehmann J.R., Lombardi J.A., Braga de Oliveira A. Antiviral activity of Bignoniaceae species occurring in the State of Minas Gerais (Brazil): part 1. Lett. Appl. Microbiol. 2010, 51:469-476.
19. Bray M., Wright M.E. Progressive vaccinia. Clin. Infect. Dis. 2003, 36:766-774.
20. Bristol N. Adverse event related to smallpox vaccination. Disaster Med. Public Health Prep. 2007, 1:11-12.
21. Brum M.C., Anjos B.L., Nogueira C.E., Amaral L.A., Weiblen R., Flores E.F. An outbreak of orthopoxvirus-associated disease in horses in southern Brazil. J. Vet. Diag. Invest. 2010, 22:143-147.
22. Campos R.K., Brum M.C., Nogueira C.E., Drumond B.P., Alves P.A., Siqueira-Lima L., Assis F.L., Trindade G.S., Bonjardim C.A., Ferreira P.C., Weiblen R., Flores E.F., Kroon E.G., Abrahão J.S. Assessing the variability of Brazilian Vaccinia virus isolates from a horse exanthematic lesion: coinfection with distinct viruses. Arch. Virol. 2011, 156:275-283.
23. Charrel R.N., de Lamballerie X. Zoonotic aspects of arenavirus infections. Vet. Microbiol. 2010, 140:213-220.
24. Chaudhri G., Panchanathan V., Bluethmann H., Karupiah G. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J. Virol. 2006, 80:6339-6344.
25. Condit R.C., Moussatche N., Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 2006, 66:31-124.
26. Coras B., Essbauer S., Pfeffer M., Meyer H., Schröder J., Stolz W., Landthaler M., Vogt T. Cowpox and a cat. Lancet 2005, 365:446.
27. Costa R.V.C., Simonetti B.R., Abreu D.C., Simonetti J.P., Gonçalves M.C.R., Silva M.E.V., Brust L.A.C., Barth O.M., Schatzmayr H.G. Animal infections by vaccinia-like viruses in the state of Rio de Janeiro: 2 - Paraíba river valley. Virus Rev. Res. 2007, 12:33-37.
28. Damaso C.R., Esposito J.J., Condit R.C., Moussatché N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277:439-449.
29. Damaso C.R., Reis S.A., Jesus D.M., Lima P.S., Moussatché N. A PCR-based assay for detection of emerging vaccinia-like viruses isolated in Brazil. Diagn. Microbiol. Infect. Dis. 2007, 57:39-46.
30. da Fonseca F.G., Trindade G.S., Silva R.L., Bonjardim C.A., Ferreira P.C., Kroon E.G. Characterization of a vaccinia-like virus isolated in a Brazilian forest. J. Gen. Virol. 2002, 83:223-228.
31. daFonseca F.G., Kroon E.G., Nogueira M.L., Trindade G.S. Zoonotic vaccinia virus outbreaks in Brazil: a review. Future Virology 2011, 6:697-707.
32. D'Anunciação L., Guedes M.I.M., Oliveira T.L., Rehfeld I., Bonjardim C.A., Ferreira P.P., Trindade G.S., Lobato Z.P., Kroon E.G., Abrahão J.S. Filling one more gap: experimental evidence of horizontal transmission of Vaccinia virus between bovines and rodents. Vector Borne Zoonotic Dis. (in press).
33. Dave R.S., McGettigan J.P., Qureshi T., Schnell M.J., Nunnari G., Pomerantz R.J. SiRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology 2006, 348:489-497.
34. Dearing M.D., Dizney L. Ecology of hantavirus in a changing world. Ann. N. Y. Acad. Sci. 2010, 1195:99-112.
35. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323:464-467.
36. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55:1-13.
37. de Magalhaes J.C., Andrade A.A., Silva P.N., Sousa L.P., Ropert C., Ferreira P.C., Kroon E.G., Gazzinelli R.T., Bonjardim C.A. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. J. Biol. Chem. 2001, 276:38353-38360.
38. de Oliveira T.M., Rehfeld I.S., Siqueira J.M., Abrahão J.S., Campos R.K., dos Santos A.K., Cerqueira M.M., Kroon E.G., Lobato Z.I. Vaccinia virus is not inactivated after thermal treatment and cheese production using experimentally contaminated milk. Foodborne Pathog. Dis. 2010, 7:1491-1496.
39. de Souza Trindade G.S., da Fonseca F.G., Marques J.T., Nogueira M.L., Mendes L.C., Borges A.S., Peiró J.R., Pituco E.M., Bonjardim C.A., Ferreira P.C., Kroon E.G. Araçatuba virus: a vaccinia like virus associated with infection in humans and cattle. Emerg. Infect. Dis. 2003, 9:155-160.
40. de Souza Trindade G., Drumond B.P., Guedes M.I., Leite J.A., Mota B.E., Campos M.A., da Fonseca F.G., et al. Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J. Clin. Microbiol 2007, 45:1370-1372.
41. de Souza Trindade G., Li Y., Olson V.A., Emerson G., Regnery R.L., da Fonseca F.G., Kroon E.G., Damon I. Real-time PCR assay to identify variants of Vaccinia virus: Implications for the diagnosis of bovine vaccinia in Brazil. J. Virol. Methods 2008, 152:63-71.
42. Di Giulio D.B., Eckburg P.B. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 2004, 4:15-25.
43. Diniz S., Trindade G.S., da Fonseca F.G., Kroon E.G. An outbreak of mousepox in Swiss mice in a laboratory animal facility - case report. Arq. Braz. Med. Vet. Zootec. 2001, 53:152-156.
44. Donatele D.M., Travassos C.E.P.F., Leite J.A., Kroon E.G. Epidemiology bovine poxviruse in the Espírito Santo State. Brazil. Braz.J. Vet. Res. Anim. Sci. 2007, 44:275-282.
45. Drumond B.P., Leite J.A., da Fonseca F.G., Bonjardim C.A., Ferreira P.C., Kroon E.G. Brazilian Vaccinia virus strains are genetically divergent and differ from the Lister vaccine strain. Microbes Infect. 2008, 10:185-197.
46. Duraffour S., Snoeck R., de Vos R., van Den Oord J.J., Crance J.M., Garin D., Hruby D.E., Jordan R., De Clercq E., Andrei G. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 2007, 12:1205-1216.
47. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 2005, 11:740-747.
48. Emonet S.F., de la Torre J.C., Domingo E., Sevilla N. Arenavirus genetic diversity and its biological implications. Infect. Genet. Evol. 2009, 9:417-429.
49. Erbagci Z., Erbagci I., Almila Tuncel A. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. J. Dermatolog. Treat. 2005, 16:353-356.
50. Fang M., Sigal L.J. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 2005, 175:6829-6836.
51. The Orthopoxviruses 1989, Academic Press, San Diego, California. F. Fenner, R. Wittek, K.R. Dumbell (Eds.).
52. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Early efforts at control: variolation, vaccination, and isolation and quarantine. Smallpox and its Eradication 1989, World Health Organization, Geneva.
53. Ferreira J.M., Drumond B.P., Guedes M.I., Pascoal-Xavier M.A., Almeida-Leite C.M., Arantes R.M., Mota B.E., Abrahão J.S., Alves P.A., Oliveira F.M., Ferreira P.C., Bonjardim C.A., Lobato Z.I., Kroon E.G. Virulence in murine model shows the existence of two distinct populations of Brazilian Vaccinia virus strains. PLoS One 2008, 3:e3043.
54. Ferreira J.M., Abrahão J.S., Drumond B.P., Oliveira F.M., Alves P.A., Pascoal-Xavier M.A., Lobato Z.I., Bonjardim C.A., Ferreira P.C., Kroon E.G. Vaccinia virus: shedding and horizontal transmission in a murine model. J. Gen. Virol. 2008, 89:2986-2991.
55. Fonseca F.G., Lanna M.C., Campos M.A., Kitajima E.W., Peres J.N., Golgher R.R., Ferreira P.C., Kroon E.G. Morphological and molecular characterization of the poxvirus BeAn 58058. Arch. Virol. 1998, 143:1171-1186.
56. Frandsen J., Enslow M., Bowen A.R. Orf parapoxvirus infection from a cat scratch. Dermatol. Online J. 2011, 17:9.
57. Fundação Nacional de Saúde Manual de Controle de Roedores, Fundação Nacional de Saúde 2002, Manual de controle de roedores Brasília, Ministério da Saúde, Brazil.
58. Gammon D.B., Snoeck R., Fiten P., Krecmerova M., Holy A., De Clercq E., Opdenakker G., Evans D.H., Andrei G. Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 2008, 82:12520-12534.
59. Geerinck K., Lukito G., Snoeck R., De Vos R., De Clercq E., Vanrenterghem Y., Degreef H., Maes B. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 2001, 64:543-549.
60. Grosenbach D.W., Berhanu A., King D.S., Mosier S., Jones K.F., Jordan R.A., Bolken T.C., Hruby D.E. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. USA 2010, 107:838-843.
61. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 2003, 9:1131-1137.
62. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3:196-200.
63. Henderson D.A. Samllpox the death of a disease 2009, Prometheus Book, New York, pp. 79-105.
64. Honlinger B., Huemer H.P., Romani N., Czerny C.P., Eisendle K., Hopfl R. Generalized cowpox infection probably transmitted from a rat. Br. J. Dermatol. 2005, 153:451-453.
65. Huggins J., Goff A., Hensley L., Mucker E., Shamblin J., Wlazlowski C., Johnson W., Chapman J., Larsen T., Twenhafel N., Karem K., Damon I.K., Byrd C.M., Bolken T.C., Jordan R., Hruby D.L. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53:2620-2625.
66. Jesus D.M., Moussatche N., Damaso C.R. In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC. Int. J. Antimicrob. Agents 2009, 33:75-79.
67. Jones K.E., Patel N.G., Levy M.A., Storeygard A., Balk D., Gittleman J.L., Daszak P. Global trends in emerging infectious diseases. Nature 2008, 451:990-993.
68. Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., Mucker E., Shamblin J., Bolken T.C., Wlazlowski C., Johnson W., Chapman J., Twenhafel N., Tyavanagimatt S., Amantana A., Chinsangaram J., Hruby D.E., Huggins J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 2009, 53:1817-1822.
69. Keith K.A., Hitchcock M.J., Lee W.A., Holy A., Kern E.R. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 2003, 47:2193-2198.
70. Kulesh D.A., Baker R.O., Loveless B.M., Norwood D., Zwiers S.H., Mucker E., Hartmann C., Herrera R., Miller D., Christensen D., Wasieloski L.P., Huggins J., Jahrling P.B. Smallpox and pan-orthopox virus detection by real-time 30 -minor groove binderTaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J. Clin. Microbiol. 2004, 42:601-609.
71. Kumar S., Tamura K., Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 2004, 5:150-163.
72. Lai A.C., Pogo B.G. Attenuated deletion mutants of vaccinia virus lacking the vaccinia growth factor are defective in replication in vivo. Microb. Pathog. 1989, 6:219-226.
73. Lanier R., Trost L., Tippin T., Lampert B., Robertson A., Foster S., Rose M., Painter W., O'Mahony R., Almond M., Painter G. Development of CMX001 for the Treatment of Poxvirus Infections. Viruses 2010, 2:2740-2762.
74. Langhammer S., Koban R., Yue C., Ellerbrok H. Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antiviral Res. 2011, 89:64-70.
75. Lauterbach H., Kassub R., Pätzold J., Körner J., Brückel M., Verschoor A., Chaplin P., Suter M., Hochrein H. Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice. PLoS One 2010, 5:e9659.
76. Lederman E.R., Green G.M., DeGroot H.E., Dahl P., Goldman E., Greer P.W., Li Y., Zhao H., Paddock C.D., Damon I.K. Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Clin. Infect. Dis. 2007, 44:e100-e103.
77. Leite J.A., Drumond B.P., Trindade G.S., Lobato Z.I., da Fonseca F.G., dos Santos J.R., Madureira M.C., Guedes M.I., Ferreira J.M., Bonjardim C.A., Ferreira P.C., Kroon E.G. Passatempo virus, a vaccinia virus strain. Brazil. Emerg. Infect. Dis. 2005, 11:1935-1938.
78. Leite J.A., Drumond B.P., de Souza Trindade G., Bonjardim C.A., Ferreira P.C., Kroon E.G. Brazilian Vaccinia virus strains show genetic polymorphism at the ati gene. Virus Genes 2007, 35:531-539.
79. Lin H.Y., Linn G., Liu C.B., Chen C.J., Yu K.J. An immunocompromised woman with severe molluscum contagiosum that responded well to topical imiquimod: a case report and literature review. J. Low Genit. Tract. Dis. 2010, 14:134-135.
80. Lobato Z.I.P., Trindade G.S., Frois M.C.M., Ribeiro E.B.T., Dias G.R.C., Teixeira B.M., Lima F.A., Almeida G.M.F., Kroon E.G. Outbreak of exantemal disease caused by Vaccinia virus in human and cattle in Zona da Mata Region, Minas Gerais. Arq. Bras. Med. Vet. Zootec. 2005, 57:423-429.
81. Lopes O.S., Lacerda J.P.G., Fonseca I.E.M., Castro D.P., Forattini O.P., Rabelo E.X. Cotia virus: a new agent isolated from sentinel mice in São Paulo. Brazil. Am. J. Trop. Med. Hyg. 1965, 14:156-157.
82. Maiboroda A.D. Experimental infection of Norvegian rats (Rattus norvegicus) with ratpox virus. Acta Virol. 1982, 26:288-291.
83. McLysaght A., Baldi P.F., Gaut B.S. Extensive gene gain associated with adaptive evolution of poxviruses. Proc. Natl. Acad. Sci. USA 2003, 100:15655-15660.
84. Megid J., Appolinário C.M., Langoni H., Pituco E.M., Okuda L.H. Vaccinia virus in humans and cattle in southwest region of Sao Paulo state. Brazil. Am. J. Trop. Med. Hyg. 2008, 79:647-651.
85. Medaglia M.L., Pessoa L.C., Sales E.R., Freitas T.R., Damaso C.R. Spread of cantagalo virus to northern Brazil. Emerg. Infect. Dis. 2009, 15:1142-1143.
86. Medeiros Silva D.C., Moreira-Silva E.A.S., Gomes J.A.S., da Fonseca F.G., Correa-Oliveira R. Clinical signs, diagnosis, and case reports of Vaccinia virus infections. Braz. J. Infect. Dis. 2010, 14:129-134.
87. Moss B. Poxviridae: The Viruses and Their Replication. FIELDS Virology 2007, 2906-2945. Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed. D.M.H. Knipe, M. Peter (Eds.).
88. Mota B.E., Trindade G.S., Diniz T.C., da Silva-Nunes M., Braga E.M., Urbano-Ferreira M., Rodrigues G.O., Bonjardim C.A., Ferreira P.C., Kroon E.G. Seroprevalence of orthopoxvirus in an Amazonian rural village, Acre. Brazil. Arch. Virol. 2010, 155:1139-1144.
89. Mota B.E., Gallardo-Romero N., Trindade G., Keckler M.S., Karem K., Carroll D., Campos M.A., Vieira L.Q., da Fonseca F.G., Ferreira P.C., Bonjardim C.A., Damon I.K., Kroon E.G. Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with vaccinia virus. PLoS One 2011, 6:18924.
90. Moussatché N., Damaso C.R., McFadden G. When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J. Infect. Dev. Ctries. 2008, 2:156-173.
91. Myskiw C., Piper J., Huzarewich R., Booth T.F., Cao J., He R. Nigericin is a potent inhibitor of the early stage of vaccinia virus replication. Antiviral Res. 2010, 88:304-310.
92. Nagasse-Sugahara T.K., Kisielius J.J., Ueda-Ito M., Curti S.P., Figueiredo C.A., Cruz A.S., Silva M.M., Ramos C.H., Silva M.C., Sakurai T., Salles-Gomes L.F. Human vaccinia-like virus outbreaks in São Paulo and Goiás States, Brazil: virus detection, isolation and identification. Rev. Inst. Med. Trop. Sao Paulo. 2004, 46:315-322.
93. Nitsche A., Kurth A., Pauli G. Viremia in human Cowpox virus infection. J. Clin. Virol. 2007, 40:160-162.
94. Neyts J., Leyssen P., Verbeken E., De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 2004, 48:2267-2273.
95. Panchanathan V., Chaudhri G., Karupiah G. Antiviral protection following immunization correlates with humoral but not cell-mediated immunity. Immunol. Cell Biol. 2010, 88:461-467.
96. Parker S., Handley L., Buller R.M. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol. 2008, 3:595-612.
97. Quenelle D.C., Collins D.J., Kern E.R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47:3275-3280.
98. Quenelle D.C., Collins D.J., Kern E.R. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 2004, 63:33-40.
99. Quenelle D.C., Prichard M.N., Keith K.A., Hruby D.E., Jordan R., Painter G.R., Robertson A., Kern E.R. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 2007, 51:4118-4124.
100. Quixabeira-Santos J.C., Medaglia M.L., Pescador C.A., Damaso C.R. Animal movement and establishment of vaccinia virus Cantagalo strain in Amazon biome. Brazil. Emerg. Infect. Dis. 2011, 17:726-729.
101. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., Chahroudi A., Chavan R., Feinberg M.B., Veach D., Bornmann W., Sherman M., Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11:731-739.
102. Reeves P.M., Smith S.K., Olson V.A., Thorne S.H., Bornmann W., Damon I.K., Kalman D. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J. Virol. 2011, 85:21-31.
103. Reiter M.J., Testerman T.L., Miller R.L., Weeks C.E., Tomai M.A. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukoc. Biol. 1994, 55:234-240.
104. Saijo M., Ami Y., Suzaki Y., Nagata N., Iwata N., Hasegawa H., Ogata M., Fukushi S., Mizutani T., Iizuka I., Sakai K., Sata T., Kurata T., Kurane I., Morikawa S. Diagnosis and assessment of monkeypox virus (MPXV) infection by quantitative PCR assay: differentiation of Congo Basin and West African MPXV strains. Jpn. J. Infect. Dis. 2008, 61:140-142.
105. Sbrana E., Jordan R., Hruby D.E., Mateo R.I., Xiao S.Y., Siirin M., Newman P.C., DA Rosa A.P., Tesh R.B. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 2007, 76:768-773.
106. Schatzmayr H.G., Lemos E.R., Mazur C., Schubach A., Majerowicz S., Rozental T., Tânia Maria Pacheco Schubach T.M.P., Bustamante M.C., Barth O.M. Detection of poxvirus in cattle associated with human cases in the State of Rio de Janeiro: preliminary report. Mem. Inst. Oswaldo Cruz 2000, 95:625-627.
107. Schatzmayr H.G., Costa R.V., Gonçalves M.C., Barreto D.F., Batista V.H., Silva M.E., Brust L.A., Barth O.M. Human infections caused by vaccinia-like poxviruses in Brazil. Rev. Soc. Bras. Med. Trop. 2009, 42:672-676.
108. Silva A.C., Reis B.B., Ricci Junior J.E.R., Fernandes F.S., Corrêa J.F., Schatzmayr H.G. Human infection by the cowpox virus in the microregion of Itajubá, State of Minas Gerais: case report. Rev. Soc. Bras. Med. Tropical 2008, 41:507-511.
109. Silva-Fernandes A.T., Travassos C.E.P.F., Ferreira J.M.S., Abrahão J.S., Rocha E.S.O., Ferreira F.V., dos Santos J.R., Bonjardim C.A., Ferreira P.C.P., Kroon E.G. Natural human infections with Vaccinia virus during bovine vaccinia outbreaks. J. Clin. Virol. 2009, 44:308-313.
110. Simonetti B.R., Abreu D.C., Simonetti J.P., Gonçalves M.C.R., Silva M.E.V., Barth O.M., Schatzmayr H.G. Animal infections by vaccinia-like viruses in the state of Rio de Janeiro:1-Northwestern region. Virus Rev. Res. 2007, 12:32-36.
111. Skinner R.B. Treatment of molluscum contagiosum with imiquimod 5% cream. J. Am. Acad. Dermatol. 2002, 47:S221-S224.
112. Sliva K., Schnierle B. From actually toxic to highly specific-novel drugs against poxviruses. Virol. J. 2007, 15:4-8.
113. Smee D.F., Bailey K.W., Wong M.H., Wandersee M.K., Sidwell R.W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 2004, 190:1132-1139.
114. Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 2009, 53:1007-1012.
115. Stittelaar K.J., Neyts J., Naesens L., van Amerongen G., van Lavieren R.F., Holý A., De Clercq E., Niesters H.G., Fries E., Maas C., Mulder P.G., van der Zeijst B.A., Osterhaus A.D. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006, 439:745-748.
116. Strenger V., Muller M., Richter S., Revilla-Fernandez S., Nitsche A., Klee S.R., Ellerbrok H., Zenz W. A 17-year-old girl with a black eschar. Cowpox virus infection. Clin. Infect. Dis. 2009, 48:133-134.
117. Syed T., Goswami J., Ahmadpour O.A., Ahmad S.A. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J. Dermatol. 1998, 25:309-313.
118. Tarbet E., Larson D., Anderson B.J., Bailey K.W., Wong M.H., Smee D.F. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. Antiviral Res. 2011, 90:126-133.
119. Theos A.U., Cummins R., Silverberg N.B., Paller A.S. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004, 74:134-138.
120. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J., Wagner T.L., Tomai M.A. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. 1995, 58:365-372.
121. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
122. Trindade G.S., da Fonseca F.G., Marques J.T., Diniz S., Leite J.A., De Bodt S., Van der Peer Y., Bonjardim C.A., Ferreira P.C., Kroon E.G. Belo Horizonte virus: a vaccinia-like virus lacking the A-type inclusion body gene isolated from infected mice. J. Gen. Virol. 2004, 85:2015-2021.
123. Trindade G.S., Lobato Z.I., Drumond B.P., Leite J.A., Trigueiro R.C., Gustavo M.I., da Fonseca F.G., dos Santos J.R., Bonjardim C.A., Ferreira P.C.P., Kroon E.G. Short report: Isolation of two vaccinia virus strains from a single bovine vaccinia outbreak in rural area Brazil: Implications on the emergence of zoonotic orthopoxvirus Am. J. Trop. Med. Hyg. 2006, 75:486-490.
124. Trindade G.S., Emerson G.L., Carroll D.S., Kroon E.G., Damon I.K Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 2007, 13:965-972.
125. Trindade G.S., Vilela J.M., Ferreira J.M., Aguiar P.H., Leite J.A., Guedes M.I., Lobato Z.I., Madureira M.C., da Silva M.I., da Fonseca F.G., Kroon E.G., Andrade M.S. Use of atomic force microscopy as a diagnostic tool to identify orthopoxvirus. J. Virol. Methods 2007, 141:198-204.
126. Trindade G.S., Guedes M.I., Drumond B.P., Mota B.E., Abrahão J.S., Lobato Z.I., Gomes J.A., Corrêa-Oliveira R., Nogueira M.L., Kroon E.G., da Fonseca F.G. Zoonotic vaccinia virus: clinical and immunological characteristics in a naturally infected patient. Clin. Infect. Dis. 2009, 48:e37-e40.
127. Toutous-Trellu L., Hirschel B., Piguet V., Schiffer V., Saurat J.H., Pechère M. Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients. Ann. Dermatol. Venereol. 2004, 131:445-449.
128. Tulman E.R., Delhon G., Afonso C.L., Lu Z., Zsak L., Sandybaev N.T., Kerembekova U.Z., Zaitsev V.L., Kutish G.F., Rock D.L. Genome of horsepox virus. J Virol. 2006, 80:9244-9258.
129. Tzahar E., Moyer J.D., Waterman H., Barbacci E.G., Bao J., Levkowitz G., Shelly M., Strano S., Pinkas-Kramarski R., Pierce J.H., Andrews G.C., Yarden Y. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 1998, 17:5948-5963.
130. Valadares Y.M., Brandao G.C., Kroon E.G., Filho J.D., Oliveira A.B., Braga F.C. Antiviral activity of Solanum paniculatum extract and constituents. Z. Naturforsch. C 2009, 64:813-818.
131. Vestergaard L., Vinner L., Andersen K.E., Fomsgaard A. Identification of cowpox infection in a 13-year-old Danish boy. Acta Derm. Venereol. 2008, 88:188-190.
132. Vigne S., Germi R., Duraffour S., Larrat S., Andrei G., Snoeck R., Garin D., Crance J.M. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Antivir. Ther. 2008, 13:357-368.
133. Vigne S., Duraffour S., Andrei G., Snoeck R., Garin D., Crance J.M. Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir. Antimicrob. Agents Chemother. 2009, 53:2579-2588.
134. Vora S., Damon I., Fulginiti V., Weber S.G., Kahana M., Stein S.L., Gerber S.I., Garcia-Houchins S., Lederman E., Hruby D., Collins L., Scott D., Thompson K., Barson J.V., Regnery R., Hughes C., Daum R.S., Li Y., Zhao H., Smith S., Braden Z., Karem K., Olson V., Davidson W., Trindade G., Bolken T., Jordan R., Tien D., Marcinak J. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 2008, 46:1555-1561.
135. Wagner T.L., Ahonen C.L., Couture A.M., Gibson S.J., Miller R.L., Smith R.M., Reiter M.J., Vasilakos J.P., Tomai M.A. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999, 191:10-19.
136. Wilson D.E., Reeder D.M. Mammal Species of the World: A Taxonomic and Geographic Reference, 3rd ed 2005, Johns Hopkins University Press, Baltimore, Maryland, pp. 2.142.
137. Xu R., Johnson A.J., Liggitt D., Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 2004, 172:6265-6271.
138. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005, 79:13139-13149.